PacBio’s latest announcement: The long and short of It
On the first day of American Society of Human Genetics meeting, PacBio rolls out new long and short-read sequencers…music group Maroon 5.
Facing regulatory block, Illumina’s $1.2B PacBio buyout falls apart
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
presented by
Sponsored
Health IT
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
FTC moves to block Illumina’s $1.2B acquisition of PacBio
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.